Empyrean Neuroscience Overview

  • Year Founded
  • 2019

Year Founded

  • Status
  • Private

  • Latest Deal Type
  • 2ndary - Private

  • Investors
  • 1

Empyrean Neuroscience General Information

Description

Developer of a genetic engineering platform designed to treat neuropsychiatric and neurologic diseases. The company's platform helps to genetically engineer small molecule therapeutics from fungi and plants, enabling healthcare professionals to treat neuroactive compound disorders of the central nervous system.

Contact Information

Website
www.empyrean.bio
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • 3 Columbus Circle
  • New York, NY 10019
  • United States
Primary Industry
Biotechnology
Other Industries
Other Healthcare Technology Systems
Corporate Office
  • 3 Columbus Circle
  • New York, NY 10019
  • United States

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Empyrean Neuroscience Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
2. Secondary Transaction - Private Completed Pre-Clinical Trials
1. Early Stage VC (Series A) 18-Oct-2022 Completed Pre-Clinical Trials
To view Empyrean Neuroscience’s complete valuation and funding history, request access »

Empyrean Neuroscience Cap Table

Stock # of Shares
Authorized		 Par Value Dividend Rate (%) Original
Issue Price		 Liquidation Liquidation
Pref. Multiple		 Conversion Price % Owned
Series A
To view Empyrean Neuroscience’s complete cap table history, request access »

Empyrean Neuroscience Patents

  • 30

    Total Documents Applications and Grants

  • Total Patents Families

  • 6

    Granted

  • 9

    Pending

  • Expiring in next 12 mo

Empyrean Neuroscience Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2023130078-A2 Genetically modified mycelium for producing psychotropic alkaloids Inactive 31-Dec-2021
WO-2023130078-A3 Genetically modified mycelium for producing psychotropic alkaloids Inactive 31-Dec-2021
EP-4457336-A2 Genetically modified organisms for producing psychotropic alkaloids Pending 31-Dec-2021
EP-4457336-A4 Genetically modified organisms for producing psychotropic alkaloids Pending 31-Dec-2021
US-12104179-B2 Genetically modified organisms for producing psychotropic alkaloids Active 31-Dec-2021 C12N9/1007
To view Empyrean Neuroscience’s complete patent history, request access »

Empyrean Neuroscience Investors (1)

Investor Name Investor Type Holding Investor Since Participating Rounds
Candy Ventures Venture Capital Minority
To view Empyrean Neuroscience’s complete investors history, request access »

Ready to get started?

Request a free trial

Empyrean Neuroscience FAQs

  • When was Empyrean Neuroscience founded?

    Empyrean Neuroscience was founded in 2019.

  • Where is Empyrean Neuroscience headquartered?

    Empyrean Neuroscience is headquartered in New York, NY.

  • What industry is Empyrean Neuroscience in?

    Empyrean Neuroscience’s primary industry is Biotechnology.

  • Is Empyrean Neuroscience a private or public company?

    Empyrean Neuroscience is a Private company.

  • What is Empyrean Neuroscience’s current revenue?

    The current revenue for Empyrean Neuroscience is .

  • How much funding has Empyrean Neuroscience raised over time?

    Empyrean Neuroscience has raised $22M.

  • Who are Empyrean Neuroscience’s investors?

    Candy Ventures has invested in Empyrean Neuroscience.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process